The company now expects full-year adjusted earnings before interest, tax, depreciation and amortization to grow between 2% and 7%, down from a prior estimate of 3% to 8%.
The new guidance reflects an uncertain macro-economic and geopolitical environment and foreign-exchange effects that may weigh on all three business segments, Merck said Thursday. A murky tariff situation led to a slight adjustment at its biggest division, the life-science unit.
Merck shares fell as much as ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.
